Clinical trials: Compensated Advanced Chronic Liver Disease
Advanced Chronic Liver Disease, Portal Hypertension
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Zinc homeostasis could play a role in advanced chronic liver disease (cACLD) and its supplementation has been linked with improvement in liver function, decrease of hepatic complications and reduction in hepatocellular carcinoma…
- Conditions
- Advanced Chronic Liver Disease, Portal Hypertension, Hepatocellular Carcinoma
- Trial name
- NCT06434753
- Testing
- Zinc Acexamate
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Compensated Advanced Chronic Liver Disease
Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)
Compensated advanced chronic liver disease (cACLD) commonly indicates severe fibrosis and compensated cirrhosis at risk of developing clinically significant portal hypertension (CSPH) and hepatic decompensation.
- Trial name
- NCT05100485
- Testing
- Esophagogasrtoduodendoscopy, Hepatic venous pressure gradient
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Advanced Chronic Liver Disease, Surgery--Complications
Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery
The ELASTO-SURGERY study aims to evaluate the prognostic role of portal hypertension evaluated by non-invasive methods in predicting post-operative morbidity (at 90 days) and mortality (at 365 days) in patients with advanced…
- Trial name
- NCT04615091
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Compensated Advanced Chronic Liver Disease, Variceal Hemorrhage
Spleen Stiffness Combined With Liver Stiffness Measured by 2D-SWE for the Screening of High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS2004)
Variceal hemorrhage is the serious complication in patients with compensated advanced chronic liver disease (cACLD). To evaluate the bleeding risk of varices, esophagogastroduodenoscopy (EGD) should be performed.
- Trial name
- NCT04546360
- Testing
- Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.
- Where
- 6 sites in China
- Volunteers
- 381 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Chronic Liver Disease
Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in MASLD Related Compensated Advanced Chronic Liver Disease.
Patients with chronic liver disease (CLD) are at risk of developing clinically significant portal hypertension (CSPH). In the Baveno VI consensus a new term "compensated advanced chronic liver disease (cACLD)'' has been proposed…
- Trial name
- NCT05044663
- Testing
- No intervention
- Where
- India
- Volunteers
- 325 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Advanced Chronic Liver Disease, NASH
Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.
Hypothesis: The severity of portal hypertension in compensated advanced chronic liver disease (cACLD) can be assessed using vibration controlled transient elastography (VCTE) via the FibroScan® 502 Touch by measuring SS (splenic…
- Trial name
- NCT03778411
- Testing
- VCTE with splenic stiffness measurement
- Where
- United States
- Volunteers
- 298 people
- Sponsor
- Indiana University
Compensated Advanced Chronic Liver Disease, Portal Hypertension
The Precise Selection of Stent Diameter for Portal Hypertension Patients With TIPS
The precise planning of TIPS, especially individual selection of stent diameter, is a hot and difficult topic in the field. We have successfully developed a non-invasive technology to evaluate hepatic venous pressure gradient and…
- Trial name
- NCT04421118
- Testing
- a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Compensated Advanced Chronic Liver Disease, Varices Needing Treatment
CHESS Criteria for Varices Screening in Compensated Advanced Chronic Liver Disease (CHESS2001/APPHA2001)
Variceal hemorrhage is the serious complication in patients with compensated advanced chronic liver disease (cACLD). To evaluate the bleeding risk of varices in cACLD, esophagogastroduodenoscopy (EGD) should be performed.
- Trial name
- NCT04307264
- Testing
- Esophagogasrtoduodendoscopy, liver stiffness measurement
- Where
- 15 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Steatohepatitis, Nonalcoholic, Steatosis of Liver
Ketogenic Diet in MASLD-related cACLD
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD.
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis of Liver, Cirrhosis, Liver
- Trial name
- NCT06537466
- Testing
- Mediterranean diet, Very Low Ketogenic Diet
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Portal Hypertension Related to Cirrhosis, Esophageal Varices
2D-shear Wave Spleen Elastography in Clinically Significant Portal Hypertension and High-risk Varices
The primary objective of this study is to evaluate the role of spleen shear wave elastography (SWE-SSM) for ruling in and ruling out clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic…
- Trial name
- NCT07122622
- Where
- Italy
- Volunteers
- 450 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Compensated Advanced Chronic Liver Disease
CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102)
Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension.
- Trial name
- NCT04975477
- Testing
- Esophagogasrtoduodendoscopy and liver stiffness, hepatic venous pressure gradient
- Where
- 7 sites in China, Egypt and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Portal Hypertension, Chronic Advanced Liver Disease
Velacur by Sonic Incytes for Portal Hypertension
This is a cross sectional study that evaluates the relationship between LSM (liver stiffness measurement) by Liver Incytes in patients with cACLD (compensated advanced chronic liver disease) and manifestations of portal…
- Trial name
- NCT04576897
- Testing
- Velacur
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Indiana University
Chronic Hepatitis C, Chronic Liver Disease
Long Term Follow-up of Hepatitis C Cured Patients
Objectives: The general objective of the present project is to gain a better understanding of disease outcome in cACLD patients treated with the new oral DAA.
- Conditions
- Chronic Hepatitis C, Chronic Liver Disease, Cirrhosis
- Trial name
- NCT03246048
- Volunteers
- 300 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Liver Cirrhosis, Liver Fibrosis
Liver and Spleen Stiffness Measured by TE and 2D-SWE for Diagnosis of CSPH in Patients With cACLD
A observational diagnostic study will be conducted to compare the performance of liver stiffness and spleen stiffness measured by 2D-shear wave elastography (2D-SWE) and transient elastography (TE) for diagnosing clinically…
- Conditions
- Liver Cirrhosis, Liver Fibrosis, Portal Hypertension
- Trial name
- NCT06147947
- Testing
- Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Liver Cirrhosis, Liver Fibrosis
Liver and Spleen Stiffness Measured by TE and 2D-SWE for Diagnosis of GOV in Patients With cACLD
A observational diagnostic study will be conducted to compare the performance of liver stiffness and spleen stiffness measured by 2D-shear wave elastography (2D-SWE) and transient elastography (TE) for diagnosing gastroesophageal…
- Conditions
- Liver Cirrhosis, Liver Fibrosis, Portal Hypertension
- Trial name
- NCT06144437
- Testing
- Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Compensated Advanced Chronic Liver Disease
Impact of Metabolic Disorders on cACLD Outcomes
This multicenter, prospective, cohort study is designed to investigate how metabolic disorders (such as obesity, diabetes, and high cholesterol) influence the progression of liver disease in patients with compensated advanced…
- Trial name
- NCT07534046
- Testing
- Observational Study
- Volunteers
- 4,307 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Chronic Liver Diseases
Correlation of Liver and Spleen Stiffness by RT-2D-SWE and Severity of Portal Hypertension by HVPG
Portal hypertension (PH) results from the increase of portal flow resistance in fibrotic tissue of the liver in patients with chronic liver diseases, leading to complications such as varices formation and variceal bleeding…
- Trial name
- NCT02653846
- Testing
- RT-2D-SWE measurement, HVPG measurement
- Where
- Croatia
- Volunteers
- 50 people
- Sponsor
- University Hospital Dubrava
Hepatitis C
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced…
- Trial name
- NCT02319031
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 10 sites in Australia, France
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Advanced Chronic Liver Disease
REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study
Background: Advanced liver scarring leads to liver failure, liver cancer and premature death. It mainly affects people in the working age group (18-65 years) and is the only major cause of death that is still increasing every…
- Trial name
- RESUS (NCT05663944)
- Testing
- Sirolimus 0.5Mg Tab, 1st MRI scan, 1st Percutaneous or Endoscopic Ultrasound guided liver biopsy
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Nottingham University Hospitals NHS Trust